Impact of Public Policy and COVID-19 Pandemic on Hepatitis C Testing and Treatment in France, 2014–2021
Viruses · 2024
DOI: 10.3390/v16050792 ↗Kurz gefasst
Fachartikel in der Zeitschrift Viruses, 2024. Verfasst von Cécile Brouard und 6 weiteren Autor:innen. Beteiligte Einrichtung: Santé Publique France, The National Public Health Agency, 94415 Saint-Maurice, France. Hauptthemen laut MEDLINE: COVID-19, Antiviral Agents, Hepatitis C, Public Policy. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Given the World Health Organization’s target to eliminate the hepatitis C virus (HCV) by 2030, we assessed the impact of French public policies and the COVID-19 pandemic on HCV testing and initiation of direct-antiviral agents (DAAs). Using the French National Health Data System, we identified individuals living in metropolitan France with at least one reimbursement for an anti-HCV test and those with a first delivery of DAAs between 1 January 2014 and 31 December 2021. During this period, the annual number of people tested increased each year between 3.3 (in 2015) and 9.3% (in 2021), except in 2020, with a drop of 8.3%, particularly marked in April (−55.0% compared to February 2020). A return to pre-pandemic testing levels was observed in 2021. The quarterly number of patients initiating DAAs presented an upward trend from Q1-2014 until mid-2017, with greater increases in Q1-2015, and Q1- and Q2-2017, concomitant with DAA access policies and availability of new therapies. Then, quarterly numbers decreased. A 65.5% drop occurred in April compared to February 2020. The declining DAA initiations since mid-2017, despite new measures improving access and screening efforts, could be due to the shrinking pool of patients requiring treatment and a need to increase awareness among undiagnosed infected people. Further action is needed to eliminate HCV in France.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Santé Publique France, The National Public Health Agency, 94415 Saint-Maurice, France.
- Caisse Nationale de l'Assurance Maladie, 75986 Paris, France.
ORCID-Profile: Cécile Brouard, Nicolas Drewniak
Zitieren
APA
Brouard, C., Schwager, M., Expert, A., Drewniak, N., Laporal, S., de Lagasnerie, G., & Lot, F. (2024). Impact of Public Policy and COVID-19 Pandemic on Hepatitis C Testing and Treatment in France, 2014–2021. Viruses. https://doi.org/10.3390/v16050792
Vancouver
Brouard C, Schwager M, Expert A, Drewniak N, Laporal S, de Lagasnerie G, et al. Impact of Public Policy and COVID-19 Pandemic on Hepatitis C Testing and Treatment in France, 2014–2021. Viruses. 2024. doi:10.3390/v16050792
BibTeX
@article{Brouard2024,
author = {Brouard, Cécile and Schwager, Manon and Expert, Aude and Drewniak, Nicolas and Laporal, Stella and de Lagasnerie, Grégoire and Lot, Florence},
title = {Impact of Public Policy and COVID-19 Pandemic on Hepatitis C Testing and Treatment in France, 2014–2021},
journal = {Viruses},
year = {2024},
doi = {10.3390/v16050792}
}
EUVIMED